C3.ai
AI
$11.84
-1.33%
C3.ai, Inc. is an enterprise artificial intelligence software company that sells a platform-as-a-service for building and deploying large-scale AI applications, alongside a portfolio of pre-built industry-specific applications and a generative AI product line, serving customers across North America, Europe, the Middle East, Asia Pacific, and the rest of the world. The company positions itself as a pure-play enterprise AI platform vendor, distinct from hyperscalers and analytics incumbents, though its roughly 764 employees and sub-$2 billion market cap place it firmly in the small-cap tier against far larger competitors. The investor narrative has shifted decisively from growth story to turnaround watch: a surprise CEO change in 2026, a founder departure, and a 25.5% year-over-year revenue decline have dominated headlines, with coverage framing the stock as either a generational value opportunity or a falling knife. Management's cost-restructuring push and a Q4 earnings beat that prompted the CEO to declare "game on" have stabilized sentiment somewhat, but the central debate remains whether the company can reverse sales execution problems and reaccelerate growth before its cash pile and patience run out.…
AI
C3.ai
$11.84
Related headlines
Investment Opinion: Should I buy AI Today?
Rating: Hold (speculative, small position only). The core thesis is that C3.ai's fortress balance sheet (current ratio 6.64, debt-to-equity 0.0085, $149.00 million cash) and an ~80% PS de-rating from 27.17x to 4.96x provide optionality if revenue merely stops contracting, but a 25.46% YoY revenue decline and -$154.33 million trailing free cash flow mean the turnaround is unproven and the stock is a show-me story rather than a confirmed recovery. With only 5 covering analysts split between one Outperform (Northland, upgraded October 12, 2026) and four cautious-to-bearish ratings (Morgan Stanley Underweight, DA Davidson Underperform, Citizens/Canaccord/Needham at Hold), there is no consensus target to anchor upside, so the rating rests on fundamentals rather than sentiment.
Supporting evidence is genuinely two-sided. On valuation, PS of 4.96x and PB of 1.90x sit at the bottom of multi-year bands (PS peaked at 79.52x in October 2021; PB range 1.50x-5.21x), yet 4.96x is not cheap for a business shrinking 25% with a -187.6% operating margin and -177.2% net margin. On operations, gross margin recovered to 31.83% in the July 2026 quarter from 21.94% in April 2026 and operating expenses fell to $114.94 million from $121.65 million sequentially, but revenue has flatlined near $52 million for three straight quarters ($53.26M, $51.60M, $52.38M) after $75.15 million in October 2025. On cash, the latest quarter's positive $2.06 million FCF was flattered by a $34.67 million working capital swing and $59.23 million of stock-based compensation, while shares outstanding rose from 135.4 million to 155.0 million over the year — roughly 14% dilution. Momentum is the brightest data point: +18.44% over six months and +14.38% over three months versus -0.54% and -4.91% for the S&P 500, with 3-month relative strength of +19.29.
The biggest risks that could invalidate the thesis are (1) continued revenue contraction below the ~$52 million quarterly floor, which would make 4.96x PS expensive rather than cheap; (2) a dilutive capital raise or strategic-alternatives process at a distressed valuation given the burn versus cash position; and (3) failed sales execution under the new CEO following the 2026 leadership change and founder departure. This Hold would upgrade to Buy if quarterly revenue stabilizes above $55 million with gross margin holding above 35% and FCF ex-working-capital improving, or if PS compresses below 4x on a stabilized revenue base; it would downgrade to Sell on a break below the $8.15 support or another quarter of double-digit YoY decline. Verdict: fairly valued to modestly expensive relative to its deteriorating fundamentals, but cheap relative to its own history — a speculative option on stabilization, not a value trap nor a bargain.
Sign up to view all
AI 12-Month Price Forecast
The forward view is genuinely balanced: the valuation has already priced in enormous pessimism (PS down ~80% from peak, PB of 1.90x near the low end of its 1.50x-5.21x band), and the balance sheet removes near-term solvency risk, but the fundamental deterioration is measurable while the turnaround remains aspirational. The base case (55%) assumes revenue stabilizes near $52 million and the stock chops between roughly $10 and $13, with the bull case (20%) requiring a genuine revenue inflection that forces a re-rating toward 6-7x PS and the bear case (25%) pricing a resumed decline or dilutive raise back toward the $8.15 low. Analyst sentiment offers little support — four of five covering analysts are Hold or worse and revenue estimates span roughly $160 million — so the stock is likely to trade on company-specific news flow rather than consensus. I would upgrade to bullish if quarterly revenue prints above $55 million with gross margin above 35% and FCF ex-working-capital improving, and downgrade to bearish on a break below $8.15 or another quarter of double-digit YoY decline.
Wall Street consensus
Coverage is thin, with only 5 analysts contributing estimates, and the institutional ratings skew cautious: recent actions include Northland Capital Markets upgrading to Outperform from Market Perform on October 12, 2026, but Citizens, Canaccord Genuity, and Needham sitting at Market Perform or Hold, DA Davidson maintaining Underperform, and Morgan Stanley at Underweight. The consensus is therefore neutral-to-bearish despite the lone upgrade, and the estimated EPS average of $0.40 (range $0.37411 to $0.42437) alongside estimated revenue averaging $1.68 billion (range $1.60 billion to $1.76 billion) implies expectations for a dramatic rebound from the current $52.38 million quarterly run-rate. No explicit average price target is provided in the data, so implied upside cannot be calculated, but the estimate dispersion and the bearish tilt of the ratings suggest limited conviction in a near-term re-rating.
The target and estimate range is wide, with revenue estimates spanning roughly $160 million between the low and high ends, which signals high uncertainty about the company's trajectory and weak consensus formation. The high end of the range likely assumes successful execution of the restructuring, stabilization of the customer base, and a return to growth that justifies multiple expansion from the current 4.96x PS, while the low end prices in continued contraction, margin compression, and further share dilution. The presence of both an Outperform upgrade and an Underperform rating within weeks of each other, combined with only 5 covering analysts, means price discovery is inefficient and the stock is prone to sharp moves on limited news flow, so investors should weight the fundamental cash burn and revenue trend more heavily than the sparse and divided analyst sentiment.
Bulls vs Bears: AI Investment Factors
The bear case currently carries stronger evidence: revenue is shrinking 25.46% YoY, net margin is -177.2%, and trailing free cash flow is -$154.33 million, so the fundamental deterioration is measurable while the turnaround is still aspirational. The bull case rests on a genuinely fortress balance sheet (current ratio 6.64, debt-to-equity 0.0085, $149.00 million cash), a PS multiple compressed roughly 80% from 27.17x to 4.96x, and improving technical momentum with 3-month relative strength of +19.29 against a declining S&P 500. The single most important tension is whether the cost restructuring and new CEO can stabilize the revenue base before the cash pile and investor patience run out — if quarterly revenue stops eroding from the ~$52 million level, the depressed multiple offers real optionality, but if contraction continues, the 4.96x PS is not cheap for a shrinking, loss-making business. Analyst sentiment (4 of 5 cautious or bearish) and the wide $160 million revenue estimate dispersion confirm that conviction in a near-term re-rating is low, making this a show-me story rather than a confirmed recovery.
Bullish
- Fortress balance sheet, minimal leverage: Debt-to-equity is just 0.0085 and the current ratio is 6.64, with $149.00 million of cash at the end of the July 2026 quarter. This gives C3.ai multiple years of runway to execute a turnaround without solvency risk, a rare luxury for a company burning $154.33 million of trailing free cash flow.
- Valuation at multi-year lows: The PS ratio has collapsed from 27.17x in July 2026 and 79.52x at the October 2021 peak to just 4.96x today, roughly an 80% de-rating, while PB of 1.90x sits near the bottom of its 1.50x-5.21x historical band. If revenue merely stabilizes, multiple expansion alone could drive meaningful upside from these depressed levels.
- Momentum and relative strength turning up: The stock is up 18.44% over six months and 14.38% over three months versus a 4.91% decline in the S&P 500, with 3-month relative strength of +19.29 and 1-month of +9.09. At $11.69 it sits roughly 97% of the way up its 180-day range of $8.15-$12.79, signaling buyers are accumulating on strength.
- Margin recovery and cost restructuring: Gross margin recovered to 31.83% in the July 2026 quarter from 21.94% in April 2026, and operating expenses fell to $114.94 million from $121.65 million sequentially. The Q4 earnings beat and CEO's "game on" commentary suggest the restructuring is beginning to show measurable traction.
Bearish
- Revenue contracting 25.5% year-over-year: The July 2026 quarter delivered $52.38 million of revenue, down 25.46% YoY, with sequential erosion from $75.15 million in October 2025 to $51.60 million in April 2026. A shrinking top line means the company is compressing into its cost base, and no turnaround thesis works until customer churn and deal deferrals are reversed.
- Enormous losses relative to revenue: The latest quarter posted a net loss of $92.81 million on $52.38 million of revenue, a -177.2% net margin, with operating margin at -187.6% and EBITDA of -$89.25 million. Operating expenses of $114.94 million (including $46.55 million R&D and $41.61 million sales and marketing) dwarf gross profit of just $16.67 million.
- Persistent cash burn funded by dilution: Trailing-twelve-month free cash flow is -$154.33 million, and the prior quarter alone burned $53.32 million. Shares outstanding rose from 135.4 million to 155.0 million over the past year, so shareholders are being diluted roughly 14% annually to fund losses, and the latest quarter's positive $2.06 million FCF was flattered by a $34.67 million working capital swing and $59.23 million of stock-based compensation.
- Analyst consensus neutral-to-bearish: Of 5 covering analysts, Citizens, Canaccord, and Needham sit at Market Perform or Hold, DA Davidson maintains Underperform, and Morgan Stanley is at Underweight, with only Northland at Outperform. Revenue estimates span roughly $160 million between low and high ends, signaling weak conviction and high uncertainty about the trajectory.
AI Technical Analysis
C3.ai is in a recovery phase within a longer-term downtrend: the stock is down 22.99% over the trailing year and 14.98% year-to-date, yet the current price of $11.69 sits roughly 97% of the way up its 180-day range of $8.15 to $12.79, having rallied 18.44% over six months. That positioning near the top of the recent range signals momentum and improving relative strength rather than overextension, particularly since the 1-year decline still leaves the stock well below where it traded a year ago. The 60.53% max drawdown underscores how violent the prior de-rating was, and the current advance looks like a base-building recovery off that capitulation low.
Short-term momentum is clearly accelerating and diverging bullishly from the longer-term trend: the stock is up 4.10% over the past month and 14.38% over three months, versus a 22.99% one-year decline, and it has decisively outperformed the S&P 500, which fell 4.99% over one month and 4.91% over three months. Relative strength readings confirm the turn, with a 1-month relative strength of +9.09 and a 3-month figure of +19.29, even as the 1-year relative strength remains deeply negative at -32.58. The most recent session added 2.72% on volume of roughly 4.22 million shares, suggesting buyers are stepping in on strength rather than fading the move, though the stock's history of sharp reversals argues for confirmation before extrapolating.
Key technical levels are well defined: resistance sits at the 180-day high of $12.79, and a breakout above that level would signal a genuine trend change and likely invite momentum buyers who have been waiting for the recovery to prove itself, while support rests at the $8.15 low, and a breakdown below that would invalidate the recovery and re-open the downside. The stock's beta is not available in the provided data, but the 60.53% max drawdown and the wide $4.64 range between the 180-day low and high imply volatility well in excess of the broad market, which matters for position sizing. Traders should treat the $12.79 resistance and $8.15 support as the risk-defining boundaries, with the current $11.69 price offering roughly 9% upside to resistance and 30% downside to support, an asymmetric setup that favors tight stops.
Beta
—
—
Max Drawdown
-60.5%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-26.4%
Cumulative gain past year
| Period | AI Return | S&P 500 |
|---|---|---|
| 1m | +2.7% | -3.7% |
| 3m | +17.5% | -2.9% |
| 6m | +31.1% | +0.2% |
| 1y | -26.4% | +10.1% |
| ytd | -13.9% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AI Fundamental Analysis
The revenue trajectory is contracting sharply and represents the core problem with the investment case: the most recent quarter (ended July 31, 2026) delivered revenue of $52.38 million, down 25.46% year-over-year, and the multi-quarter trend shows sequential erosion from $75.15 million in the October 2025 quarter to $53.26 million in January 2026, $51.60 million in April 2026, and $52.38 million in July 2026. The segment detail is thin, with professional services at $3.21 million, engineering services at $1.76 million, and service fees at $1.45 million, but the collapse in total revenue points to subscription and platform weakness rather than a mix issue. For the investment case, a 25% decline means the company is shrinking into its cost base, and any turnaround thesis must first answer why customers are leaving or deferring before growth can be restored.
Profitability remains deeply negative despite some margin improvement: the latest quarter posted a net loss of $92.81 million on $52.38 million of revenue, a net margin of -177.2%, with gross margin of 31.83% and gross profit of just $16.67 million against $35.71 million of cost of revenue. Gross margin has been volatile and generally compressing, falling from 40.43% in the October 2025 quarter to 21.94% in April 2026 and recovering to 31.83% in July 2026, while operating margin sits at -187.6% and EBITDA is -$89.25 million. The losses are enormous relative to revenue and are being driven by operating expenses of $114.94 million, including $46.55 million of R&D and $41.61 million of sales and marketing, so the path to profitability requires either a dramatic revenue recovery or far deeper cost cuts than have been executed so far.
The balance sheet is the one genuine bright spot: debt-to-equity is just 0.0085, the current ratio is a very strong 6.64, and cash at the end of the latest quarter was $149.00 million, giving the company ample near-term liquidity and essentially no leverage risk. However, free cash flow on a trailing-twelve-month basis is -$154.33 million, and the latest quarter's positive free cash flow of $2.06 million was flattered by a $34.67 million working capital swing and $59.23 million of stock-based compensation, while the prior quarter burned $53.32 million of free cash flow. ROE of -71.95% reflects both the losses and a shrinking equity base, and with shares outstanding rising from 135.4 million to 155.0 million over the past year, dilution is quietly funding the burn, which is a real cost to shareholders even with the fortress-like current ratio.
Quarterly Revenue
$52375000.0B
2026-07
Revenue YoY Growth
-25.5%
YoY Comparison
Gross Margin
31.8%
Latest Quarter
Free Cash Flow
$-154334000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AI Overvalued?
Because net income is negative (-$92.81 million in the latest quarter, with trailing EPS of -$0.38), the PE ratio is not meaningful, and the appropriate primary metric is the price-to-sales ratio, which stands at 4.96x on a market cap of roughly $1.24 billion. The trailing PE of -2.64x and forward PE of -0.05x are artifacts of losses and should be disregarded, while the negative EV/EBITDA of -2.59x and negative PCF of -6.57x confirm the company is unprofitable on every cash-based measure. The 4.96x PS multiple is the key number, and it implies the market is still paying a meaningful premium for a business whose revenue is shrinking 25% year-over-year.
Peer comparison is constrained by the absence of a formal industry-average multiple in the provided data, but the historical ratios offer a clear internal benchmark: the PS ratio has collapsed from 27.17x in the July 2026 quarter and 25.02x in April 2026 to the current 4.96x, a roughly 80% de-rating that reflects the market's repricing of the growth story. Against a software sector where profitable growers often command 6-10x sales, a 4.96x multiple for a declining, loss-making business is not obviously cheap, and the premium is hard to justify given the -25.46% revenue growth and -187.6% operating margin. The discount to the company's own history is real, but it is a discount earned by deteriorating fundamentals rather than an inefficiency.
Historically, the stock's PS ratio has ranged from roughly 22.87x (October 2022) to 79.52x (October 2021) during the growth era, and the current 4.96x is at the very bottom of that multi-year band, while the PB ratio of 1.90x is also near the low end of its historical 1.50x-5.21x range. Being at historical lows cuts both ways: it can signal a value opportunity if the business stabilizes, or it can signal that the market expects further deterioration, and with revenue still contracting and cash burn persistent, the burden of proof sits squarely on management to demonstrate a floor. Until the PS multiple stops compressing on falling estimates, the valuation offers little margin of safety despite the optically low absolute numbers.
PE
-2.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
31.1x
Industry PE ~31.1x*
EV/EBITDA
-2.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe and quantifiable. The company lost $92.81 million on $52.38 million of revenue in the July 2026 quarter (-177.2% net margin), with operating expenses of $114.94 million against gross profit of only $16.67 million, meaning the cost base must roughly halve or revenue must double before breakeven is plausible. Trailing free cash flow of -$154.33 million against $149.00 million of cash implies the balance sheet, while unlevered (debt-to-equity 0.0085), provides only about one year of runway at the current burn absent further dilution — and shares already rose from 135.4 million to 155.0 million over the past year. Revenue concentration in a shrinking enterprise AI platform business, with a 25.46% YoY decline and sequential erosion from $75.15 million to $52.38 million, means the operational risk is existential rather than cyclical.
Market and competitive risks compound the fundamental picture. At 4.96x PS, the stock is not statistically expensive versus profitable software growers at 6-10x sales, but it is a premium multiple for a business contracting 25% with a -187.6% operating margin, leaving room for further compression if estimates fall. Competition from hyperscalers and analytics incumbents, combined with the 2026 CEO change and founder departure, raises execution risk precisely when sales momentum is most fragile, and the thin coverage of 5 analysts (with Morgan Stanley Underweight and DA Davidson Underperform) means negative news flow can move the stock sharply. Beta is not provided, but the 60.53% max drawdown and the $4.64 range between the 180-day low and high imply volatility well in excess of the market, and the stock's 1-year relative strength of -32.58 versus the S&P 500's +9.59% shows how violently it can underperform in a risk-off rotation.
In a worst-case scenario, revenue contraction persists through the next several quarters, the new CEO's restructuring fails to stabilize the customer base, and the company is forced into a dilutive capital raise or strategic alternatives at a distressed valuation. From the current $11.69 price, a retest of the 180-day low of $8.15 would represent roughly -30%, and a full re-rating toward the prior capitulation zone implied by the 60.53% max drawdown would be far worse. The asymmetry is unfavorable: roughly 9% upside to the $12.79 resistance versus 30% downside to the $8.15 support, which argues for tight risk controls and position sizing well below a core holding.
FAQ
The most severe risk is financial: -$154.33 million TTM free cash flow against $149.00 million of cash implies roughly one year of runway at the current burn, and shares already rose from 135.4 million to 155.0 million over the past year, so a dilutive raise is a live threat. Second is operational: revenue fell 25.46% YoY to $52.38 million with operating expenses of $114.94 million against gross profit of only $16.67 million, meaning the cost base must roughly halve or revenue must double before breakeven. Third is execution and competitive risk, with a 2026 CEO change and founder departure weakening sales momentum against hyperscalers and analytics incumbents. Fourth is market/valuation risk: thin coverage of five analysts, including Morgan Stanley at Underweight and DA Davidson at Underperform, plus a 60.53% max drawdown, means negative news flow can move the stock violently.
The base case carries 55% probability and targets $10.00-$13.00, assuming revenue stabilizes near $52 million per quarter, opex holds near $114.94 million, gross margin stays in the 30-35% range, and no dilutive raise is needed. The bull case at 20% probability targets $14.50-$16.50 and requires revenue to inflect above $55 million with gross margin back above 35-40%, prompting a re-rating from 4.96x toward 6-7x PS. The bear case at 25% targets $6.50-$8.15 and assumes contraction resumes, losses stay near -$90 million per quarter, and a distressed raise or strategic review forces a retest of the 180-day low. The base case is most likely because the last three quarters have already flatlined near $52 million, but the 25% bear weight reflects that the cash burn leaves little room for error.
It is cheap relative to its own history but not cheap relative to its fundamentals. The PS ratio of 4.96x is down roughly 80% from 27.17x in July 2026 and 79.52x at the October 2021 peak, and PB of 1.90x sits near the bottom of its 1.50x-5.21x band, so on a historical basis the stock looks washed out. However, 4.96x sales is still a premium multiple for a business contracting 25.46% with a -187.6% operating margin and -177.2% net margin, and PE, EV/EBITDA, and PCF are all negative and therefore meaningless as valuation anchors. The market is effectively pricing a floor in revenue without paying for growth. Until estimates stop falling, the low absolute multiple reflects earned deterioration rather than an inefficiency, so the stock is best described as fairly valued to modestly expensive on fundamentals.
Only as a small, speculative position, not as a core holding. The risk/reward is asymmetric in the wrong direction at $11.69: roughly 9% upside to the 180-day high of $12.79 versus about 30% downside to the $8.15 low, against a backdrop of 25.46% YoY revenue decline and -$154.33 million trailing free cash flow. The bull case depends on the balance sheet ($149.00 million cash, current ratio 6.64, debt-to-equity 0.0085) and a PS multiple already down ~80% to 4.96x, which offers real optionality if revenue stabilizes. But with four of five analysts at Hold or worse and no consensus price target to anchor upside, there is no sentiment cushion. It is a reasonable buy only for investors with high risk tolerance, a multi-year horizon, and position sizes small enough to absorb a retest of $8.15.
It is better suited to a patient, multi-year holding than to short-term trading, but only in small size. The turnaround thesis requires several quarters of evidence that revenue has bottomed and margins are holding, so a minimum holding period of 18-24 months is reasonable to let the new CEO's restructuring play out. Short-term traders face a stock with a 60.53% max drawdown and a $4.64 range between the 180-day low and high, which demands tight stops around the $8.15 support and $12.79 resistance. There is no dividend (payout ratio 0) and no earnings visibility, with trailing EPS of -$0.38, so there is no income or valuation floor to support a passive long hold. Momentum is currently favorable (+18.44% over six months, 3-month relative strength of +19.29), but that is a trading signal, not an investment thesis.